title: High-risk type-2 diabetes mellitus patients, without prior ischemic events, have normal blood platelet functionality profiles: a cross-sectional study.
abstract: BACKGROUND
  Patients with type 2 diabetes mellitus (DM) display a predisposition for vascular disease. Platelets taken from vasculopathic diabetic patients, show enhanced stimuli-induced activation and aggregation responses. Aspirin remains the cornerstone antiplatelet agent for secondary prevention of vascular complications among diabetic patients, yet evidence of its efficacy and safety in primary prevention are conflicting. Our aim was to assess whether high risk diabetic patients, without previous ischemic events, have abnormal platelet functionality profiles.
  
  
  METHODS
  The study included 82 diabetic patients and 86 matched non-diabetic patients without prior ischemic events nor treatment with anti-platelet medications. Blood samples were analyzed for platelet markers of activation, turnover and leukocyte-platelet interactions.
  
  
  RESULTS
  Our final analysis included 122 males (74 %), with a mean age of 61 years. Mean platelet volume (MPV) was similar between the diabetic patients and controls (9.2 fL for both). Following activation, PAC-1 binding and P-selectin expression were found comparable between the diabetic patients and controls (83 % versus 81 % and 76 % versus 74 %, respectively). Leukocyte-platelet aggregates (LPAs) were similar between the diabetic patients and controls (18 % versus 17 %, respectively). Neutrophil-platelet aggregates (NPAs) and monocyte-platelet aggregates (MPAs) were also found similar in the diabetic patients and controls. Elevated fasting plasma glucose was associated with increased LPAs rates.
  
  
  CONCLUSIONS
  High risk type-2 diabetes mellitus patients, without prior ischemic events, have normal blood platelet functionality profiles.
authors.affiliation: Department of Internal Medicine D and Hypertension Unit, The Chaim Sheba Medical Center, Derech Sheba 1, Tel Hashomer, Ramat-Gan, 52621, Israel. Gadi.Shlomai@sheba.health.gov.il.|The Dr. Pinchas Borenstein Talpiot Medical Leadership Program 2013, Tel-Aviv, Israel. Gadi.Shlomai@sheba.health.gov.il.|Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. Gadi.Shlomai@sheba.health.gov.il.
authors.forename: Gadi
authors.initials: G
authors.lastname: Shlomai
authors.affiliation: Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. tali.haran@gmail.com.
authors.forename: Tal
authors.initials: T
authors.lastname: Haran-Appel
authors.affiliation: Department of Oncology, Chaim Sheba Medical Center, Tel Hashomer, Israel. Talsella@gmail.com.
authors.forename: Tal
authors.initials: T
authors.lastname: Sella
authors.affiliation: Department of Internal Medicine D and Hypertension Unit, The Chaim Sheba Medical Center, Derech Sheba 1, Tel Hashomer, Ramat-Gan, 52621, Israel. yonigros@gmail.com.
authors.forename: Yoni
authors.initials: Y
authors.lastname: Grossman
authors.affiliation: Institute of Thrombosis and Hemostasis, Chaim Sheba Medical Center, Tel Hashomer, Israel. Hagit.Hauschner@sheba.health.gov.il.
authors.forename: Hagit
authors.initials: H
authors.lastname: Hauschner
authors.affiliation: Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. Nurit.Rosenberg@sheba.health.gov.il.|Institute of Thrombosis and Hemostasis, Chaim Sheba Medical Center, Tel Hashomer, Israel. Nurit.Rosenberg@sheba.health.gov.il.
authors.forename: Nurit
authors.initials: N
authors.lastname: Rosenberg
authors.affiliation: Department of Internal Medicine D and Hypertension Unit, The Chaim Sheba Medical Center, Derech Sheba 1, Tel Hashomer, Ramat-Gan, 52621, Israel. ehud.grossman@sheba.health.gov.il.|Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. ehud.grossman@sheba.health.gov.il.
authors.forename: Ehud
authors.initials: E
authors.lastname: Grossman
mesh_terms: D000368:Aged; D001792:Blood Platelets / Q000378:metabolism* / Q000502:physiology; D016022:Case-Control Studies; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D005260:Female; D006801:Humans; D006835:Hydrazones; D007962:Leukocytes; D008297:Male; D063847:Mean Platelet Volume; D008875:Middle Aged; D009000:Monocytes; D009504:Neutrophils; D019007:P-Selectin / Q000378:metabolism*; D010879:Piperazines; D010974:Platelet Aggregation; D010979:Platelet Function Tests
chemical_list: C514579:(4-benzylpiperazin-1-yl)acetic acid (3-allyl-2-hydroxybenzylidene)hydrazine; D006835:Hydrazones; D019007:P-Selectin; D010879:Piperazines; C546937:SELP protein, human